Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company’s bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer’s Disease (AD).
ITCI pinelines are strong.
Q3 2019(9/30/19): Cash 255M. Loss 34.72M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 156，no change
Shares hold: 42835.5k shares. no change
shares% hold: 77.51%，no change